The health crisis has completely changed life as we know it and caused a significant shift in consumer demand for immune-boosting products, vitamins, and supplements. Now, due to growing awareness around heath, the wellness supplements market is projected to reach $386.29 billion by 2027, growing at a CAGR of 6.45%. Dietary supplement sales in the US, Canada, and the UK rose sharply during the pandemic and are expected to remain elevated, creating a lucrative opportunity for companies like Pfizer Inc. (NYSE:PFE), GlaxoSmithKline (NYSE:GSK), Archer Daniels Midland (NYSE:ADM), Abbott Laboratories (NYSE:ABT), and Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF).
...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
Consumers Continue Flocking to Immune-Boosting Supplements as Health Crisis Rages On